Clarity Medical Group Holding Limited
1406.HK
Hong Kong Stock Exchange0.36
HKD
+0.02
- -
ISIN
KYG2181S1084
Return %
Stock
S&P500
1Y
- -
24.99
3Y
- -
70.19
5Y
- -
77.45
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Bo Jiang
- Full Time Employees
- 105
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- Ginza Plaza Kowloon Hong Kong
- IPO Date
- Feb 18, 2022
- Website
- claritymedic.com
- Similar Companies
- Business
- Clarity Medical Group Holding Limited provides ophthalmic healthcare services, focusing on refractive and other eye treatments, supported by comprehensive consultation, examination, and related medical services. Main Products and Services - Refractive surgery platform and treatments: SMILE surgery, LASIK surgery, SMILE Pro, SILK refractive technology, and ICL implantations - Comprehensive ophthalmic care: standard cataract surgeries, pars plana vitrectomy (PPV), laser procedures, and a broad range of ophthalmic treatments and surgeries - Diagnostic and consultation services: visual acuity testing, refraction, anterior segment examination, fundal examination, intraocular pressure measurement - Ancillary services: medical consultation, ophthalmic examinations, and sale of prescriptions and related products - Center network services: outpatient ophthalmic care through multiple centers and clinics offering integrated services Geographic Operations - Headquarters: Kowloon, Hong Kong - Primary market focus: Hong Kong ophthalmology market with a growing regional footprint in metropolitan centers - Regional expansion via new medical centers and partnerships to broaden service access Founding Year and Corporate Structure - Founded in 2005 - Incorporated in the Cayman Islands with limited liability; operates as an investment holding company with ownership of ophthalmic clinics and service platforms Latest Major Company Changes - Strategic partnership and product platform expansion: launches of advanced refractive treatment portfolio through a collaboration with a major medical device/tech partner, expanding the fully comprehensive refractive offerings in Hong Kong to include LASIK, SMILE, SMILE Pro, SILK, and ICL - Operational enhancements: openings or relocation of clinics to enhanced facilities (New Mong Kok Centre, New Tsim Sha Tsui medical centre) to improve patient experience and expand capacity - Market positioning updates: emphasis on technology leadership in ophthalmology within Hong Kong through integrated refractive technologies and expanded service lines - Performance and resilience: continued emphasis on high-quality ophthalmic care with a focus on patient visitation and new patient bookings, supported by expanded service portfolio and modern treatment platforms Additional Context - Industry and segments: healthcare services with a focus on ophthalmology, including refractive surgery, cataract and vitreoretinal procedures, laser and other ophthalmic interventions - Target markets: private patients seeking elective refractive and comprehensive ophthalmic care; institutions and clinics seeking specialized ophthalmology services - Subsidiaries/parent: operates as an investment holding company with ownership over ophthalmic medical centers and treatment platforms; number of staff and corporate structure aligned with expansion across Hong Kong centers - Regulatory and disclosures: grouped under listed company disclosures in relevant markets, with citations to company announcements detailing strategy, expansions, and product platform launches Note: This description reflects publicly available information and the company’s stated strategic directions, including refractive and ophthalmic treatment offerings, center expansions, and partnerships driving the enhanced refractive portfolio in Hong Kong.